Edgewise Therapeutics (EWTX) AI Stock Analysis

• Market Cap: $3.52B
• Dividend Yield: N/A
• Average Volume (3M): 840.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.10
• Revenue Growth: N/A
• EPS Growth: -5.73%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 107,270,520
• 10 Day Avg. Volume: 739,588
• 30 Day Avg. Volume: 840,711
• PEG Ratio: -1.23
• Price to Book (P/B): 4.89
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.76
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -19.30
• 1Y Price Target: $44.17
• Price Target Upside: 34.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -2.09
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $31.00 ▼(-5.55% Downside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is driven primarily by mixed fundamentals: a strong, low-debt balance sheet offsets very weak operating performance with no revenue and rising losses/cash burn. Technicals are supportive with an established uptrend and positive momentum indicators, while valuation remains constrained by negative earnings and no dividend.

Positive Factors

Strong cash reserves

A cash and marketable securities balance of ~$530M provides a durable runway to fund clinical programs and organizational growth without immediate reliance on dilutive financing, enabling sustained R&D execution and optionality around partnership or regulatory timing over the next 2–6 months.

Negative Factors

No revenue

Absence of product revenue means the business lacks internal recurring cash generation, leaving R&D and operations entirely dependent on capital markets or partners. This structural profile increases financing risk and reduces margin diversification over the medium term.

Edgewise Therapeutics Business Overview & Revenue Model

Company Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause o...

Read more

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause o...

How the Company Makes Money

Edgewise Therapeutics generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company makes money by conducting clinical trials, gaining regulatory approvals, and ultimately marketing its t...

Read more

Edgewise Therapeutics generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company makes money by conducting clinical trials, gaining regulatory approvals, and ultimately marketing its t...

Edgewise Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-2.27M	0.00	0.00	0.00	0.00
EBITDA	-165.53M	-156.54M	-112.63M	-71.12M	-42.94M
Net Income	-167.79M	-133.81M	-100.16M	-67.64M	-42.81M
Balance Sheet
Total Assets	552.60M	486.82M	340.04M	367.10M	285.23M
Cash, Cash Equivalents and Short-Term Investments	530.11M	470.17M	318.39M	351.95M	280.79M
Total Debt	3.99M	4.74M	5.41M	4.41M	0.00
Total Liabilities	30.35M	27.60M	21.20M	20.39M	10.85M
Stockholders Equity	522.26M	459.22M	318.83M	346.72M	274.38M
Cash Flow
Free Cash Flow	-143.82M	-110.34M	-97.69M	-58.18M	-34.17M
Operating Cash Flow	-143.82M	-109.03M	-91.95M	-52.63M	-33.51M
Investing Cash Flow	-32.79M	-184.66M	102.89M	-70.58M	-242.23M
Financing Cash Flow	196.09M	249.25M	53.17M	129.64M	186.38M

Edgewise Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 32.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EWTX, the sentiment is Positive. The current price of 32.82 is above the 20-day moving average (MA) of 31.33, above the 50-day MA of 30.24, and above the 200-day MA of 21.18, indicating a bullish trend. The MACD of 0.97 indicates Negative momentum. The RSI at 58.74 is Neutral, neither overbought nor oversold. The STOCH value of 79.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EWTX.

Edgewise Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EWTX	61 Neutral	$3.52B	-12.72	-31.97%	―	―	-5.73%
PHVS	57 Neutral	$1.71B	-7.95	-70.76%	―	―	-20.08%
VERA	56 Neutral	$3.21B	-10.86	-59.72%	―	―	-53.44%
VRDN	54 Neutral	$1.53B	-5.48	-58.44%	―	23340.07%	18.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JANX	50 Neutral	$908.22M	―	-11.55%	―	-23.37%	-42.45%
BHVN	44 Neutral	$1.38B	-1.64	-688.89%	―	―	18.76%